6533b7dbfe1ef96bd12709a8

RESEARCH PRODUCT

Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus Gemcitabine.

Antonio FebbraroAngelica PetrilloFortunato CiardielloFernando De VitaJole VentrigliaGiuseppe TirinoValentina GambardellaA. DianaMaria Maddalena LaterzaAndrés CervantesMichele OrdituraMarisol Huerta AlvaroB. Savastano

subject

OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseGemcitabineOncologyPancreatic cancerInternal medicineImmunologymedicineOverall survivalNeutrophil to lymphocyte ratiobusinesshuman activitieshealth care economics and organizationsNab-paclitaxelmedicine.drug

description

e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...

https://doi.org/10.1200/jco.2016.34.15_suppl.e15737